Remove Avalon Remove Funding Remove Technology
article thumbnail

Avalon Ventures Gets Commitments Of $103M In New, $300M Fund

socalTECH

La Jolla-based venture capital investor Avalon Ventures has just received a $103M commitment to a new, $300M fund, according to a regulatory filing by the firm. The filing indicates that, so far, the fund has 26 investors in the first sale. READ MORE>>.

Avalon 100
article thumbnail

Avalon Ventures Closes $200M Fund

socalTECH

San Diego-based Avalon Ventures , a venture capital firm focused on early stage high tech, digital media, and life sciences firms, said today that it has closed on $200M in capital commitments for its latest fund. Avalon said that the fund, Avalon Ventures IX, LP, is the ninth and largest fund for the company.

Avalon 140
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup

Xconomy

[ Note: The headline has been corrected to better describe the company’s type of funding. Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. 9/27/16, 2:09 p.m. Bregua Corp., We’re not inventing anything on the ADC,” he said.

Avalon 40
article thumbnail

Avelas Biosciences Raises $6.85M

socalTECH

San Diego-based Avelas Biosciences announced today that it has raised $6.85M in a Series B funding round, for the company''s technology for illuminating cancer cells. The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor.

Avalon 138
article thumbnail

Avelas Biosciences Gains $7.65M For Tumor Visualization

socalTECH

San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients.

Avalon 138
article thumbnail

Synthorx Raises $10M

socalTECH

San Diego-based Synthorx , a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures. RA Capital Management's Andrew Levin joins the company's board with the funding.

Avalon 100
article thumbnail

Avelas Biosciences Finds $7.4M

socalTECH

in a Series B funding. The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. The technology behind the Avelas product is based on research conducted at UC San Diego. READ MORE>>.

Avalon 147